Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.
This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.
Jorge Plutzky, M.D. is Director, Preventive Cardiology at Brigham and Women’s Hospital (BWH), and is on the faculty of Harvard Medical School
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- LDL-c: Done Deal, Next Epigenetics?A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
Prof Kausik Ray
- LDL-c: Done Deal, Next Epigenetics?The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Prof. Erik Stroes, MD